Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

The order directs the HHS Secretary to communicate most-favored-nation price targets to pharmaceutical manufacturers within 30 days, with the goal of aligning what American patients pay with the lowest prices charged to comparable developed nations. It also directs the HHS Secretary to facilitate direct-to-consumer purchasing programs for manufacturers willing to sell at most-favored-nation prices, and directs the Secretary of Commerce and the U.S. Trade Representative to take all necessary action to stop foreign countries from suppressing pharmaceutical prices below fair market value at Americans' expense.

If manufacturers do not make significant progress toward those targets, a second tier of conditional actions activates: HHS must propose a rulemaking to formally impose most-favored-nation pricing; the FDA Commissioner may certify drug importation under the FDCA and issue consistent waiver rules; the Attorney General and FTC Chair must pursue antitrust enforcement against anti-competitive practices; Commerce must review controls on pharmaceutical exports; and the FDA must review and potentially revoke drug approvals for unsafe or improperly marketed products. None of the second-tier actions are self-executing — each depends on an agency determination that sufficient progress has not been made.

American patients and consumers of prescription drugs, pharmaceutical manufacturers that sell in U.S. and international markets, foreign governments whose drug pricing practices face new trade scrutiny, and federal healthcare programs such as Medicare and Medicaid that pay for prescription drugs.

If price targets are accepted or enforced through subsequent rulemaking, Americans who pay for brand-name drugs — through Medicare, private insurance, or out of pocket — could see prices fall toward the lowest prices paid in peer nations. Pharmaceutical manufacturers face potential antitrust action, importation competition, and export restrictions if they do not comply.

The order operates in two phases. Phase one is a 30-day diplomatic push: HHS sends formal price targets to manufacturers. Phase two is conditional — if manufacturers fail to make significant progress, each agency listed in Section 5(b) independently exercises its assigned authority: HHS initiates rulemaking, FDA evaluates importation certification, DOJ and FTC file antitrust suits, and Commerce reviews export controls. No single trigger event or timeline is specified for phase two, and the order's standard severability and no-private-rights clauses apply throughout.